AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02084472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine:petroleum jelly 2:1
Description: patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
Study NCT04040166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI of carotid arteries with 68Ga DOTATATE
Description: PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
Study NCT00715039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: 1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
Study NCT00715039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
Study NCT00715039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
Study NCT01246921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone proprionate 0.05% cream
Description: Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
Study NCT01181336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Study NCT01009502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
Study NCT03254498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff
Description: It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
Study NCT03254498 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cap assisted colonoscopy (CAC)
Description: cap assisted colonoscopy (CAC)
Study NCT03655223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory Testing
Description: If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
Study NCT02630368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and JX-594 dose escalation
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Study NCT02630368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and JX-594
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Study NCT02630368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
Study NCT02630368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and JX-594 and Cyclophosphamide
Description: Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Study NCT04034940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
Description: Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
Study NCT00990912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
Study NCT00990912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
Study NCT00990912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
Study NCT03449433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03449433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03449433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Administered SC
Study NCT00378248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy
Description: 18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
Study NCT04546724 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
Study NCT04546724 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
Study NCT00562939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccines + CPG 7909
Description: Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
Study NCT00562939 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal vaccines
Description: Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
Study NCT00520663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-SB649868
Description: SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
Study NCT01382706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT03574350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KS in Kangaroo Position
Description: KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
Study NCT03574350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KS in incubator
Description: The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
Study NCT01382706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01382706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01382706 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT01382706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01181336 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FLU-v Control
Description: Adjuvant only or water for injection only Administration: a single subcutaneous injection
Study NCT01289028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT01987609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Study NCT01987609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT04020393 — intervention group
Intervention type: PROCEDURE
Intervention: SPGB
Description: SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
Study NCT04094727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presumptive treatment with Artemether-lumefantrine (AL)
Description: All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
Study NCT04094727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced vector control
Description: The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round.
Study NCT01872286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKE-1
Study NCT01872286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam SB2
Study NCT02871544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BNP and NGAL
Study NCT02871544 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BNP and NGAL
Study NCT00378248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient individual psychotherapy
Description: Eclectic individual psychotherapy in private practice
Study NCT02162212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Shoulder Movement Program
Description: A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity.
Study NCT02162212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADA Guideline Instructed
Description: The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
Study NCT01541917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based coping skills training
Description: This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
Study NCT01541917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online disease education
Description: The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease.
Study NCT02273570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
Study NCT02273570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D
Description: Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
Study NCT00266695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: 32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
Study NCT03793010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single Intra-articular injection
Study NCT02300155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregvit®
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
Study NCT02300155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orifer F®
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
Study NCT04598386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR Lotion - AMP Human Performance
Description: Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
Study NCT04598386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
Study NCT00396643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
Study NCT00396643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 fatty acids
Description: The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
Study NCT01608061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS-f on
Description: deep brain stimulation of the fornix
Study NCT04234958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Specific protocol including 4 osteopathic techniques targeting the pericardium
Study NCT04234958 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: Sham therapy mimicking the osteopathic techniques applied to experimental group
Study NCT03610139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
Study NCT03610139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
Study NCT01428336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 ug ACTH stimulation test
Description: 1 ug cortrosyn dose
Study NCT01608061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS-f off
Description: deep brain stimulation of the fornix turned off
Study NCT02776137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 20mg/m2/w for 6 weeks
Study NCT02776137 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60Gy in 30 fractions over 6 weeks
Study NCT02565212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast,mometazon froat
Study NCT02565212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast,mometazon froat
Study NCT02508935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XARTEMIS XR
Description: XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
Study NCT03190031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance respiratory muscle training
Description: Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea